Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
Neoplasm Malignant
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 2
- Patients
- 730 (planned)
- Started
- Aug 18, 2021
- Main results expected
- Mar 22, 2027
- Fully finished
- Mar 22, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Arm 1: Number of Participants Who Experience at Least One Dose-limiting Toxicity (DLT)
Measured over: Up to approximately 21 days
Arm 1: Number of Participants Who Experience at Least One Adverse Event (AE)
Measured over: Up to approximately 67 months
Arm 1: Number of Participants Who Discontinue Study Treatment Due to an AE
Measured over: Up to approximately 67 months
Confirmed Objective Response Rate (ORR) Per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
Measured over: Up to approximately 67 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04976634 · record last updated 2025-04-06 · checked 2026-11-09 15:47 UTC